Augoustides-Savvopoulou P, Luka Z, Karyda S, Stabler S P, Allen R H, Patsiaoura K, Wagner C, Mudd S H
Pediatric Biochemistry/Metabolic Laboratory, Hippocration General Hospital, Thessaloniki, Greece.
J Inherit Metab Dis. 2003;26(8):745-59. doi: 10.1023/B:BOLI.0000009978.17777.33.
We report studies of a Greek boy of gypsy origin that show that he has severe deficiency of glycine N -methyltransferase (GNMT) activity due to apparent homozygosity for a novel mutation in the gene encoding this enzyme that changes asparagine-140 to serine. At age 2 years he was found to have mildly elevated serum liver transaminases that have persisted to his present age of 5 years. At age 4 years, hypermethioninaemia was discovered. Plasma methionine concentrations have ranged from 508 to 1049 micro mol/L. Several known causes of hypermethioninaemia were ruled out by studies of plasma metabolites: tyrosinaemia type I by a normal plasma tyrosine and urine succinylacetone; cystathionine beta-synthase deficiency by total homocysteine of 9.4-12.1 micro mol/L; methionine adenosyltransferase I/III deficiency by S -adenosylmethionine (AdoMet) levels elevated to 1643-2222 nmol/L; and S -adenosylhomocysteine (AdoHcy) hydrolase deficiency by normal AdoHcy levels. A normal plasma N -methylglycine concentration in spite of elevated AdoMet strongly suggested GNMT deficiency. Molecular genetic studies identified a missense mutation in the coding region of the boy's GNMT gene, which, upon expression, retained only barely detectable catalytic activity. The mild hepatitis-like manifestations in this boy are similar to those in the only two previously reported children with GNMT deficiency, strengthening the likelihood of a causative association. Although his deficiency of GNMT activity may well be more extreme, his metabolic abnormalities are not strikingly greater. Also discussed is the metabolic role of GNMT; several additional metabolite abnormalities found in these patients; and remaining questions about human GNMT deficiency, such as the long-term prognosis, whether other individuals with this defect are currently going undetected, and means to search for such persons.
我们报告了一项对一名吉普赛裔希腊男孩的研究,该研究表明,由于编码甘氨酸N-甲基转移酶(GNMT)的基因发生新突变,导致其明显纯合,致使该酶活性严重缺乏,该突变使第140位天冬酰胺变为丝氨酸。在他2岁时,发现其血清肝转氨酶轻度升高,此情况一直持续到他现在5岁。4岁时,发现他患有高甲硫氨酸血症。血浆甲硫氨酸浓度在508至1049微摩尔/升之间。通过对血浆代谢物的研究排除了几种已知的高甲硫氨酸血症病因:血浆酪氨酸和尿琥珀酰丙酮正常排除了I型酪氨酸血症;总同型半胱氨酸为9.4 - 12.1微摩尔/升排除了胱硫醚β-合酶缺乏症;S-腺苷甲硫氨酸(AdoMet)水平升高至1643 - 2222纳摩尔/升排除了甲硫氨酸腺苷转移酶I/III缺乏症;AdoHcy水平正常排除了S-腺苷同型半胱氨酸(AdoHcy)水解酶缺乏症。尽管AdoMet升高,但血浆N-甲基甘氨酸浓度正常,强烈提示GNMT缺乏。分子遗传学研究在该男孩的GNMT基因编码区发现了一个错义突变,该突变表达后仅保留了几乎无法检测到的催化活性。该男孩的轻度肝炎样表现与之前仅有的两名报道的GNMT缺乏儿童相似,这增强了因果关联的可能性。尽管他的GNMT活性缺乏可能更为严重,但他的代谢异常并不明显更严重。还讨论了GNMT的代谢作用;在这些患者中发现的其他几种代谢物异常;以及关于人类GNMT缺乏症的剩余问题,如长期预后、是否目前还有其他有此缺陷的个体未被发现以及寻找此类人员的方法。